$CRSP
CRISPR Therapeutics AG

2022 Q1 Form 10-Q Financial Statement

#000095017022008495 Filed on May 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $940.0K $539.0K
YoY Change 74.4% 243.31%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $58.67M $24.50M
YoY Change 139.46% 25.0%
% of Gross Profit
Research & Development $118.2M $70.62M
YoY Change 67.44% 30.31%
% of Gross Profit
Depreciation & Amortization $6.039M $2.715M
YoY Change 122.43% 29.84%
% of Gross Profit
Operating Expenses $176.9M $115.1M
YoY Change 53.73% 56.06%
Operating Profit -$176.0M -$114.5M
YoY Change 53.63% 55.66%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $363.0K $1.955M
YoY Change -81.43% -53.8%
Pretax Income -$175.6M -$112.6M
YoY Change 55.97% 62.34%
Income Tax $3.600M $600.0K
% Of Pretax Income
Net Earnings -$179.2M -$113.2M
YoY Change 58.37% 62.29%
Net Earnings / Revenue -19065.64% -20994.99%
Basic Earnings Per Share -$2.32 -$1.51
Diluted Earnings Per Share -$2.32 -$1.51
COMMON SHARES
Basic Shares Outstanding 77.10M 75.01M
Diluted Shares Outstanding 77.10M 75.01M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $822.7M $1.620B
YoY Change -49.22% 82.11%
Cash & Equivalents $683.9M $1.126B
Short-Term Investments $138.8M $494.2M
Other Short-Term Assets $39.21M $26.00M
YoY Change 50.82% 79.31%
Inventory
Prepaid Expenses
Receivables $143.0K $200.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.261B $1.832B
YoY Change 23.37% 97.18%
LONG-TERM ASSETS
Property, Plant & Equipment $157.5M $51.91M
YoY Change 203.3% 63.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.330M $23.30M
YoY Change -81.42% 3419.64%
Total Long-Term Assets $345.6M $125.5M
YoY Change 175.35% 60.9%
TOTAL ASSETS
Total Short-Term Assets $2.261B $1.832B
Total Long-Term Assets $345.6M $125.5M
Total Assets $2.606B $1.958B
YoY Change 33.11% 94.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $27.11M $13.10M
YoY Change 106.95% 16.17%
Accrued Expenses $72.63M $49.86M
YoY Change 45.66% 127.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $113.7M $83.10M
YoY Change 36.82% 50.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.335M $69.30M
YoY Change -89.42% 479.87%
Total Long-Term Liabilities $7.335M $69.30M
YoY Change -89.42% 479.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $113.7M $83.10M
Total Long-Term Liabilities $7.335M $69.30M
Total Liabilities $361.3M $152.4M
YoY Change 137.05% 25.74%
SHAREHOLDERS EQUITY
Retained Earnings -$375.1M
YoY Change
Common Stock $2.637B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $63.00K
YoY Change
Treasury Stock Shares $180.3K
Shareholders Equity $2.245B $1.805B
YoY Change
Total Liabilities & Shareholders Equity $2.606B $1.958B
YoY Change 33.11% 94.37%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$179.2M -$113.2M
YoY Change 58.37% 62.29%
Depreciation, Depletion And Amortization $6.039M $2.715M
YoY Change 122.43% 29.84%
Cash From Operating Activities -$135.2M -$100.7M
YoY Change 34.35% 92.93%
INVESTING ACTIVITIES
Capital Expenditures $15.35M $7.024M
YoY Change 118.54% 134.84%
Acquisitions
YoY Change
Other Investing Activities -$99.17M -$160.9M
YoY Change -38.36%
Cash From Investing Activities -$114.5M -$167.9M
YoY Change -31.79% 5513.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $214.6M
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.65M 226.0M
YoY Change -95.29% 19863.87%
NET CHANGE
Cash From Operating Activities -135.2M -100.7M
Cash From Investing Activities -114.5M -167.9M
Cash From Financing Activities 10.65M 226.0M
Net Change In Cash -239.1M -42.57M
YoY Change 461.8% -21.26%
FREE CASH FLOW
Cash From Operating Activities -$135.2M -$100.7M
Capital Expenditures $15.35M $7.024M
Free Cash Flow -$150.6M -$107.7M
YoY Change 39.84% 95.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001674416
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-37923
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
CRISPR THERAPEUTICS AG
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
V8
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Baarerstrasse 14
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6300
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Zug
CY2022Q1 dei Entity Address Country
EntityAddressCountry
CH
CY2022Q1 dei City Area Code
CityAreaCode
41 (0)41
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
561 32 77
CY2022Q1 dei Security12b Title
Security12bTitle
Common Shares, nominal value CHF 0.03
CY2022Q1 dei Trading Symbol
TradingSymbol
CRSP
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
2608000
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
77457081
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
683906000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
923031000
CY2022Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1537355000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1456098000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
143000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
305000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
39212000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
38079000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
2260616000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
2417513000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
157453000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
137575000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
112000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
125000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
12123000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16913000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
171541000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
174460000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4330000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5291000
CY2022Q1 us-gaap Assets
Assets
2606175000
CY2021Q4 us-gaap Assets
Assets
2751877000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
27111000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14816000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
72632000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
91003000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1011000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
724000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11076000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12158000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
270000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
171000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
113697000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
119883000
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12323000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12323000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
227904000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
212872000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7335000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7339000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-179217000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2751877000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
940000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2606175000
CY2022Q1 us-gaap Liabilities
Liabilities
361259000
CY2021Q4 us-gaap Liabilities
Liabilities
352417000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77566721
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77170382
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77386405
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76990066
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
2407000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2391000
CY2022Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
180316
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
180316
CY2022Q1 us-gaap Treasury Stock Value
TreasuryStockValue
63000
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
63000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2634597000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2598114000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-375132000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-195915000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16893000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5067000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2244916000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2399460000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
539000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
118245000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70620000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28021000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24517000
CY2022Q1 crsp Collaboration Expense
CollaborationExpense
30646000
CY2021Q1 crsp Collaboration Expense
CollaborationExpense
19945000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
176912000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
115082000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-175972000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-114543000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
363000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1955000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
363000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1955000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-175609000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-112588000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3608000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
575000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-113163000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1805498000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2399460000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
4000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10010000
CY2022Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
740000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25745000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-11826000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-179217000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-113163000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11799000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-383000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-191043000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-113541000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.32
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77098319
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75005187
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.32
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77098319
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75005187
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1664234000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
222175000
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
3000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9784000
CY2021Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
751000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22092000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-378000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2244916000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-179217000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-113163000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6039000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2715000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
25745000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
22092000
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-6099000
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2064000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-162000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4611000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5068000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1616000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5770000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-135239000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-100663000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-762000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-539000
CY2022Q1 crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
3854000
CY2021Q1 crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
778000
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-154000
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3766000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15350000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7024000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
323140000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
323975000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
223975000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
163101000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-114515000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-167898000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
214592000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
10649000
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
11399000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10649000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
225991000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-27000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-239132000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-42565000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
939944000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1185468000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
700812000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1142903000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5888000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8847000
CY2022Q1 crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
217000
CY2021Q1 crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
2868000
CY2022Q1 crsp Leasehold Improvements Paid Directly By Landlord
LeaseholdImprovementsPaidDirectlyByLandlord
13015000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
683906000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1126059000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
12123000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16844000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
700812000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1142903000
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, revenue recognition, equity-based compensation expense and reported amounts of expenses during the period. Significant estimates in these consolidated financial statements have been made in connection with revenue recognition and equity-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
CY2021Q4 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
-1000
CY2021Q4 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
517382000
CY2022Q1 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
2099373000
CY2022Q1 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
9000
CY2022Q1 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
-16912000
CY2022Q1 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
2082470000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
517383000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1461200000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
16000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5118000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1456098000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1978583000
CY2022Q1 us-gaap Marketable Securities
MarketableSecurities
138800000
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
405600000
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
545121000
CY2022Q1 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
1000
CY2022Q1 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
-7000
CY2022Q1 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
545115000
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1554252000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
16905000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1537355000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
16000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
-5119000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1973480000
CY2022Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
534900000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1311600000
CY2022Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
9500000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
4600000
CY2022Q1 crsp Debt Securities Available For Sale Securities Remaining Maturity Greater Than Three Year
DebtSecuritiesAvailableForSaleSecuritiesRemainingMaturityGreaterThanThreeYear
0
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
201286000
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.005
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
175382000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43833000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37807000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
157453000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
137575000
CY2022Q1 us-gaap Depreciation
Depreciation
6000000.0
CY2021Q1 us-gaap Depreciation
Depreciation
2700000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8780000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23661000
CY2022Q1 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
49925000
CY2021Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
47986000
CY2022Q1 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
533000
CY2021Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
138000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4456000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4720000
CY2022Q1 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
4345000
CY2021Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
6120000
CY2022Q1 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
2321000
CY2021Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
7113000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2272000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1265000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
72632000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
91003000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25745000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22092000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7812982
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
58.07
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
820189
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
58.62
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
261280
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
39.17
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
151433
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
78.48
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8220458
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
58.35
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4757990
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
43.59
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8220458
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
58.35
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
157600000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9378791
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9635636
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3600000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.021

Files In Submission

Name View Source Status
0000950170-22-008495-index-headers.html Edgar Link pending
0000950170-22-008495-index.html Edgar Link pending
0000950170-22-008495.txt Edgar Link pending
0000950170-22-008495-xbrl.zip Edgar Link pending
crsp-20220331.htm Edgar Link pending
crsp-20220331.xsd Edgar Link pending
crsp-20220331_cal.xml Edgar Link unprocessable
crsp-20220331_def.xml Edgar Link unprocessable
crsp-20220331_htm.xml Edgar Link completed
crsp-20220331_lab.xml Edgar Link unprocessable
crsp-20220331_pre.xml Edgar Link unprocessable
crsp-ex31_1.htm Edgar Link pending
crsp-ex31_2.htm Edgar Link pending
crsp-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending